Reposted by Jean-Ehrland RICCI
Check how the combinatorial strategy composed of ALK inhibitors and a new EGFR-targeting ADC for the treatment of ALK-rearranged and EGFR-overexpressing NSCLC exerts its pharmacological synergism through activation of the mitochondria-mediated caspase cascade and the ER stress-triggered UPR.
